Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
暂无分享,去创建一个
D. Vaughan | N. Brown | G. Williams | M. Agirbasli | W. Litchfield | Gordon H. Williams | Douglas E. Vaughan | Gordon H. Williams | Mehmet Agirbasli | Nancy J Brown | Gordon H. Williams | W. R. Litchfield | Nancy J. Brown
[1] Duk-KyungKim,et al. Polymorphism of Angiotensin Converting Enzyme Gene Is Associated With Circulating Levels of Plasminogen Activator Inhibitor-1 , 1997 .
[2] W. R. Lee,et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[3] M. Margaglione,et al. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[4] M. Pfeffer,et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.
[5] M. Alessi,et al. PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events , 1997, Thrombosis and Haemostasis.
[6] D. Vaughan,et al. Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.
[7] J. Morrow,et al. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. , 1996, The Journal of pharmacology and experimental therapeutics.
[8] W. Quist,et al. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. , 1996, Circulation.
[9] D. Vaughan,et al. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. , 1995, The Journal of clinical investigation.
[10] J. Breslow,et al. Effect of fosinopril and vitamin E on LDL peroxidation and atheroclerosis progression in apo E-deficient mice , 1995 .
[11] P. Kurnik. Circadian variation in the efficacy of tissue-type plasminogen activator. , 1995, Circulation.
[12] D. Vaughan,et al. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.
[13] B. Brenner,et al. Hypertension: Pathophysiology, Diagnosis, and Management , 1994 .
[14] J. Jespersen,et al. Regulation of tissue‐type plasminogen activator‐mediated fibrinolysis by plasminogen activator inhibitor type‐1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics , 1994, Coronary artery disease.
[15] K. Alberti,et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. , 1994, Journal of the American College of Cardiology.
[16] D. Goldstein,et al. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. , 1994, Journal of chromatography. B, Biomedical applications.
[17] P. Ridker,et al. Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function , 1993, Circulation.
[18] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[19] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[20] D. Loskutoff,et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Manson,et al. Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor , 1992, Circulation.
[22] J. Emeis,et al. On the role of bradykinin in secretion from vascular endothelial cells. , 1992, Agents and actions. Supplements.
[23] T. Gelehrter,et al. Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. , 1992, Molecular endocrinology.
[24] J. Laragh,et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.
[25] J. Manson,et al. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. , 1990, Circulation.
[26] W. Chandler,et al. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. , 1990, Thrombosis research.
[27] A. Chobanian,et al. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. , 1990, Hypertension.
[28] G. Åberg,et al. Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys , 1990, Journal of cardiovascular pharmacology.
[29] T. Gelehrter,et al. Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. , 1989, Molecular endocrinology.
[30] W. Chandler,et al. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). , 1989, Circulation.
[31] A. V. van Zonneveld,et al. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Cowan,et al. American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.
[33] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[34] C. Kluft,et al. Plasminogen activator inhibitors. , 1987, Blood.
[35] R. Skidgel,et al. The angiotensin I-converting enzyme. , 1987, Laboratory investigation; a journal of technical methods and pathology.
[36] E. Braunwald,et al. Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.
[37] J. Ockene. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1985, The American journal of cardiology.
[38] M. Gilbert,et al. Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985, Blood.
[39] L. Wilkins. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. The Hypertension Detection and Follow-up Program Cooperative Research Group. , 1984, Circulation.
[40] J. Verheijen,et al. Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma , 1984, Thrombosis and Haemostasis.
[41] N. Hollenberg. The Renin‐Angiotensin System and Sodium Homeostasis , 1984, Journal of cardiovascular pharmacology.
[42] J. Laragh,et al. Use of First‐Dose Response or Plasma Renin Activity to Predict the Long‐Term Effect of Captopril: Identification of Triphasic Pattern of Blood Pressure Response , 1980, Journal of cardiovascular pharmacology.
[43] C. Sussman,et al. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. , 1979, The Journal of laboratory and clinical medicine.
[44] Skidgel Ra,et al. The angiotensin I-converting enzyme. , 1977 .
[45] D. Adams,et al. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. , 1974, The Journal of clinical investigation.
[46] J. Brown,et al. Sensitization of the Adrenal Cortex to Angiotensin II in Sodium‐Deplete Man , 1974, Circulation research.
[47] J. Sullivan,et al. Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension. , 1973, The American journal of cardiology.
[48] J. Laragh,et al. Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.